KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Accounts Payables (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Accounts Payables readings, the most recent being $15.8 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 35.92% to $15.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.8 million, a 35.92% increase, with the full-year FY2025 number at $15.8 million, up 35.92% from a year prior.
  • Accounts Payables hit $15.8 million in Q4 2025 for Biocryst Pharmaceuticals, up from $5.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $27.8 million in Q4 2021 to a low of $5.6 million in Q3 2025.
  • Median Accounts Payables over the past 5 years was $12.0 million (2022), compared with a mean of $12.8 million.
  • Biggest five-year swings in Accounts Payables: soared 90.44% in 2024 and later tumbled 58.71% in 2025.
  • Biocryst Pharmaceuticals' Accounts Payables stood at $27.8 million in 2021, then plummeted by 48.37% to $14.4 million in 2022, then surged by 45.53% to $20.9 million in 2023, then crashed by 44.27% to $11.6 million in 2024, then soared by 35.92% to $15.8 million in 2025.
  • The last three reported values for Accounts Payables were $15.8 million (Q4 2025), $5.6 million (Q3 2025), and $8.6 million (Q2 2025) per Business Quant data.